Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Gao, Wei ^a   Bing, Xue ^a,b   Li, Mingyan ^c   Yang, Zhanhua ^a   Li, Ying ^a,b,c   Chen, Hua ^a  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Weifang Medicine College   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

c Met; Carcinoma; Colorectal; LoVo cells; Nude mice; SU11274; Xenograft tumor

Indexed keywords

DIMETHYL SULFOXIDE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SCATTER FACTOR RECEPTOR; ((3Z) N (3 CHLOROPHENYL) 3 ((3,5 DIMETHYL 4 ((4 METHYLPIPERAZIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) N METHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONAMIDE); ((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RON PROTEIN; SULFONAMIDE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL ASSAY; CELL CYCLE; CELL SURVIVAL; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ADENOMA; ANIMAL; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; METASTASIS; METHODOLOGY; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875355775     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0546-3     Document Type: Article

References (28)

1. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309-25.
2. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;63:7345-55.
3. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003;63:7926-35.
4. Ma PC, Kijima T, Maulik G, et al. c-Met mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63:6272-8.
5. Puri N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor of c-Met, PHA66 inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007;67:3529-34.
6. Bellusci S, Moens G, Gaudino G, et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene. 1994;9:1091-9.
7. Jeffers M, Rong S, Anver M, Vande Woude GF. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastatic phenotype in C127 cells. Oncogene. 1996;13:853-6.
8. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA. 1997;94:701-6.
9. Gallego MI, Bierie B, Hennighausen L. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 2003;22:8498-508.
10. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1-26.
11. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003;63:5462-9.
12. Hao X, Frayling IM, Willcocks TC, Han W, Tomlinson IP, Pignatelli MN, Pretlow TP, Talbot IC. Beta-catenin expression and allelic loss at APC in sporadic colorectal carcinogenesis. Virchows Arch. 2002;440:362-6.
13. Hao X, Palazzo JP, Ilyas M, Tomlinson I, Talbot IC. Reduced expression of molecules of the cadherin/catenin complex in the transition from colorectal adenoma to carcinoma. Anticancer Res. 1997;17:2241-7.
14. Lydon NB, Druker BJ. Lessons learned from the development of imatinib. Leuk Res. 2004;28(Suppl 1):S29-38.
15. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011;103:645-61.
16. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89-103.
17. Morello S, Olivero M, Aimetti M, et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol. 2001;189:285-90.
18. Cortesina G, Martone T, Galeazzi E, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer. 2000;89:286-92.
19. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res. 2001;7:3519-25.
20. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res. 2004;10:202-11.
21. Inoue K, Chikazawa M, Karashima T, et al. Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma. Acta Med Okayama. 1998;52:305-10.
22. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 1999;29:209-48.
23. Haddad R, Lipson KE, Webb CP. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res. 2001;21:4243-52.
24. Longati P, Comoglio PM, Bardelli A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr Drug Targets. 2001;2:41-55.
25. Hov H, Holt RU, Ro TB, et al. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res. 2004;10:6686-94.
26. Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL. Small molecule c-Met inhibitor PHA-665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck. 2008;30:991-1000.
27. Watson GA, Zhang X, Stang MT, et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia. 2006;8:949-55.
28. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA. 2006;103:2316-21.